Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Medical Genetics and Applied Genomics, |
RCV001733803 | SCV001984759 | pathogenic | Achromatopsia | 2021-10-28 | criteria provided, single submitter | clinical testing | in combination with c.848G>A, p.Arg283Gln |
Labcorp Genetics |
RCV002543925 | SCV003198238 | pathogenic | not provided | 2022-07-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu584Serfs*23) in the CNGA3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 111 amino acid(s) of the CNGA3 protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CNGA3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1301856). This variant disrupts a region of the CNGA3 protein in which other variant(s) (p.Arg661His) have been determined to be pathogenic (PMID: 32913385; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV004815613 | SCV005071307 | pathogenic | Retinal dystrophy | 2020-01-01 | no assertion criteria provided | clinical testing |